The Delhi High Court has allowed Zydus Lifesciences to sell its biosimilar version of the cancer drug nivolumab, overturning a previous interim injunction. A division bench cited public interest and the drug's life-saving nature, noting the original patent's nearing expiration. Zydus is directed to maintain detailed sales accounts until the patent expires in May 2026, to ensure potential compensation for the patent holder, Bristol Myers Squibb (BMS), if they ultimately win infringement proceedings.